$2.60
1.17% today
Nasdaq, Feb 28, 05:20 pm CET
ISIN
US68235C1071
Symbol
OCX

Oncocyte Corporation Stock price

$2.57
+0.54 26.60% 1M
-0.57 18.15% 6M
+0.19 7.98% YTD
-0.39 13.18% 1Y
-26.63 91.20% 3Y
-42.63 94.31% 5Y
-159.03 98.41% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.01 0.26%
ISIN
US68235C1071
Symbol
OCX
Sector

Key metrics

Market capitalization $54.13m
Enterprise Value $54.76m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 77.13
P/S ratio (TTM) P/S ratio 76.24
P/B ratio (TTM) P/B ratio 3.54
Revenue (TTM) Revenue $710.00k
EBIT (operating result TTM) EBIT $-22.88m
Free Cash Flow (TTM) Free Cash Flow $-20.49m
Cash position $3.36m
EPS (TTM) EPS $-4.43
P/E forward negative
P/S forward 108.26
EV/Sales forward 109.52
Short interest 2.96%
Show more

Is Oncocyte Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Oncocyte Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Oncocyte Corporation forecast:

1x Buy
33%
2x Hold
67%

Analyst Opinions

3 Analysts have issued a Oncocyte Corporation forecast:

Buy
33%
Hold
67%

Financial data from Oncocyte Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.71 0.71
91% 91%
100%
- Direct Costs 1.89 1.89
80% 80%
266%
-1.18 -1.18
19% 19%
-166%
- Selling and Administrative Expenses 11 11
101% 101%
1,596%
- Research and Development Expense 9.06 9.06
52% 52%
1,276%
-22 -22
57% 57%
-3,038%
- Depreciation and Amortization 1.32 1.32
75% 75%
186%
EBIT (Operating Income) EBIT -23 -23
59% 59%
-3,223%
Net Profit -43 -43
32% 32%
-6,076%

In millions USD.

Don't miss a Thing! We will send you all news about Oncocyte Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Oncocyte Corporation Stock News

Neutral
GlobeNewsWire
17 days ago
IRVINE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend BTIG's MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, Utah.
Neutral
MCAP MediaWire
17 days ago
IRVINE, Calif., Feb. 11, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend BTIG's MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, Utah.
Neutral
MCAP MediaWire
18 days ago
IRVINE, Calif., Feb. 10, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it has entered into securities purchase agreements with existing investors for a registered direct offering (“Registered Direct Offering”) and concurrent private placement (“PIPE Offering”).
More Oncocyte Corporation News

Company Profile

OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services. The company was founded in September 2009 and is headquartered in Alameda, CA.

Head office United States
CEO Joshua Riggs
Employees 46
Founded 2009
Website www.oncocyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today